Related Experiment Videos
[Studies on cefozopran in the pediatric field]
The Japanese Journal of Antibiotics
|November 1, 1994
Summary
Cefozopran (CZOP) demonstrated favorable pharmacokinetics and high efficacy in pediatric patients. This antibiotic achieved a 94.1% clinical efficacy rate for various infections with a 94.7% bacterial eradication rate.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Therapy
Background:
- Cefozopran (CZOP) is a cephalosporin antibiotic.
- Pediatric infections require effective and safe treatment options.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical efficacy of cefozopran in pediatric patients.
- To assess the safety profile of cefozopran in this population.
Main Methods:
- Pharmacokinetic analysis of cefozopran following intravenous drip infusion at 10 and 20 mg/kg.
- Clinical evaluation of cefozopran in pediatric patients with various infections.
- Assessment of bacterial eradication and adverse events.
Main Results:
- Cefozopran exhibited an average plasma half-life of approximately 1.6-1.8 hours.
- Urinary excretion rates ranged from 53.2% to 56.2%.
- A clinical efficacy rate of 94.1% and a bacterial eradication rate of 94.7% were observed.
Conclusions:
- Cefozopran is effective and well-tolerated for treating pediatric infections.
- The pharmacokinetic profile supports its use in pediatric populations.
- Further monitoring for potential adverse effects like elevated liver enzymes is warranted.